share_log

BRII-B Covid Combination Therapy Retains Neutralizing Activity against Omicron

BRII-B Covid Combination Therapy Retains Neutralizing Activity against Omicron

BRII-B聯合治療保留對奧密克戎的中和活性
阿斯達克財經 ·  2022/07/27 04:50

BRII-B (02137.HK) announced new live virus data confirming that the amubarvimab/ romlusevimab combination, a long-acting COVID-19 monoclonal antibody therapy, retains
neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants.
The U.S. Food and Drug Administration is currently reviewing the Company's Emergency Use Authorization application for the amubarvimab/ romlusevimab combination.

BRII-B(02137.HK)公佈了新的活病毒數據,證實了長效新冠肺炎單抗療法阿米巴韋/羅魯塞米聯合治療保留了
對奧密克戎BA.4/5和BA.2.12.1 SARS-CoV-2亞型的中和活性。
美國食品和藥物管理局目前正在審查該公司對amubarvimab/romlusevimab組合的緊急使用授權申請。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論